Lineage Cell Therapeutics, Inc. Share-based Payment Arrangement, Expense
Lineage Cell Therapeutics, Inc. (LCTX) reported Share-based Payment Arrangement, Expense of $1.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-06
- Lineage Cell Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $1.60M, a 29.32% increase year-over-year.
- Lineage Cell Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $1.17M, a 3.70% decline year-over-year.
- Lineage Cell Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $1.10M, a 16.50% decline year-over-year.
- Lineage Cell Therapeutics, Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $1.20M, a 9.85% decline year-over-year.
- Lineage Cell Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2025 was $4.75M, a 6.40% decline from fiscal 2024.
- Lineage Cell Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2024 was $5.08M, a 9.42% increase from fiscal 2023.
- Lineage Cell Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2023 was $4.64M, a 8.23% increase from fiscal 2022.
- Lineage Cell Therapeutics, Inc. share-based payment arrangement, expense for fiscal 2022 was $4.29M.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.60M 10-Q · filed 2026-08-06 | $2.77M 10-Q · filed 2026-08-06 | $3.87M derived: sum of 3 quarters · filed 2026-08-06 | $5.07M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $1.17M 10-Q · filed 2026-05-12 | $2.27M derived: sum of 2 quarters · filed 2026-05-12 | $3.47M derived: sum of 3 quarters · filed 2026-05-12 | $4.71M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.30M derived: sum of 2 quarters · filed 2026-03-05 | $3.54M derived: sum of 3 quarters · filed 2026-08-06 | $4.75M 10-K · filed 2026-03-05 | ||
| 2025-09-30 | $1.20M 10-Q · filed 2025-11-06 | $2.44M derived: sum of 2 quarters · filed 2026-08-06 | $3.65M 10-Q · filed 2025-11-06 | $4.97M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $1.24M 10-Q · filed 2026-08-06 | $2.46M 10-Q · filed 2026-08-06 | $3.77M derived: sum of 3 quarters · filed 2026-08-06 | $5.10M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $1.22M 10-Q · filed 2026-05-12 | $2.53M derived: sum of 2 quarters · filed 2026-05-12 | $3.86M derived: sum of 3 quarters · filed 2026-05-12 | $5.13M derived: sum of 4 quarters · filed 2026-05-12 | ||
| 2024-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.65M derived: sum of 2 quarters · filed 2026-03-05 | $3.91M derived: sum of 3 quarters · filed 2026-03-05 | $5.08M 10-K · filed 2026-03-05 | ||
| 2024-09-30 | $1.33M 10-Q · filed 2025-11-06 | $2.60M derived: sum of 2 quarters · filed 2025-11-06 | $3.76M 10-Q · filed 2025-11-06 | $4.82M derived: sum of 4 quarters · filed 2025-11-06 | ||
| 2024-06-30 | $1.27M 10-Q · filed 2025-08-12 | $2.43M 10-Q · filed 2025-08-12 | $3.49M derived: sum of 3 quarters · filed 2025-08-12 | $4.76M derived: sum of 4 quarters · filed 2025-08-12 | ||
| 2024-03-31 | $1.16M 10-Q · filed 2025-05-13 | $2.22M derived: sum of 2 quarters · filed 2025-05-13 | $3.49M derived: sum of 3 quarters · filed 2025-05-13 | $4.77M derived: sum of 4 quarters · filed 2025-05-13 | ||
| 2023-12-31 | $1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $2.33M derived: sum of 2 quarters · filed 2025-03-10 | $3.61M derived: sum of 3 quarters · filed 2025-03-10 | $4.64M 10-K · filed 2025-03-10 | ||
| 2023-09-30 | $1.27M 10-Q · filed 2024-11-14 | $2.55M derived: sum of 2 quarters · filed 2024-11-14 | $3.58M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $1.28M 10-Q · filed 2024-08-08 | $2.31M 10-Q · filed 2024-08-08 | ||||
| 2023-03-31 | $1.03M 10-Q · filed 2024-05-09 | |||||
| 2022-12-31 | $4.29M 10-K · filed 2024-03-07 | |||||
| 2018-12-31 | $297.88M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $298.00M derived: sum of 2 quarters · filed 2020-03-12 | $298.00M 10-K · filed 2020-03-12 | $123.00K 10-K · filed 2019-03-14 | ||
| 2018-09-30 | $123.00K 10-Q · filed 2018-11-08 | $123.00K 10-Q · filed 2018-11-08 | ||||
| 2018-03-31 | $984.00K 10-Q · filed 2018-05-10 | |||||
| 2017-09-30 | $973.00K 10-Q · filed 2017-11-09 | $1.88M derived: sum of 2 quarters · filed 2017-11-09 | $2.90M 10-Q · filed 2017-11-09 | $4.55M derived: sum of 4 quarters · filed 2017-11-09 | ||
| 2017-06-30 | $905.00K 10-Q · filed 2017-08-09 | $1.93M 10-Q · filed 2017-08-09 | $3.58M derived: sum of 3 quarters · filed 2017-08-09 | $4.29M derived: sum of 4 quarters · filed 2017-11-09 | ||
| 2017-03-31 | $1.03M 10-Q · filed 2017-05-10 | $2.67M derived: sum of 2 quarters · filed 2017-05-10 | $3.38M derived: sum of 3 quarters · filed 2017-11-09 | $5.60M derived: sum of 4 quarters · filed 2017-11-09 | ||
| 2016-12-31 | $1.65M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $2.36M derived: sum of 2 quarters · filed 2017-11-09 | $4.58M derived: sum of 3 quarters · filed 2017-11-09 | $7.95M 10-K · filed 2017-03-16 | ||
| 2016-09-30 | $710.00K 10-Q · filed 2017-11-09 | $2.93M derived: sum of 2 quarters · filed 2017-11-09 | $6.30M 10-Q · filed 2017-11-09 | $10.16M derived: sum of 4 quarters · filed 2017-11-09 | ||
| 2016-06-30 | $2.22M 10-Q · filed 2017-08-09 | $5.59M 10-Q · filed 2017-08-09 | $9.45M derived: sum of 3 quarters · filed 2017-08-09 | $12.94M derived: sum of 4 quarters · filed 2017-08-09 | ||
| 2016-03-31 | $3.37M 10-Q · filed 2017-05-10 | $7.23M derived: sum of 2 quarters · filed 2017-05-10 | $10.72M derived: sum of 3 quarters · filed 2017-05-10 | $12.51M derived: sum of 4 quarters · filed 2017-05-10 | ||
| 2015-12-31 | $3.86M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $7.35M derived: sum of 2 quarters · filed 2017-03-16 | $9.14M derived: sum of 3 quarters · filed 2017-03-16 | $11.05M 10-K · filed 2017-03-16 | $11.06M 10-K · filed 2016-03-15 | |
| 2015-09-30 | $3.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $5.28M derived: sum of 2 quarters · filed 2016-11-04 | $7.19M 10-Q · filed 2016-11-04 | |||
| 2015-06-30 | $1.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $3.70M 10-Q · filed 2016-08-09 | ||||
| 2015-03-31 | $1.91M 10-Q · filed 2016-05-10 | |||||
| 2014-12-31 | $4.46M 10-K · filed 2017-03-16 | $4.46M 10-K · filed 2015-03-11 | ||||
| 2014-03-31 | $801.55K 10-Q · filed 2014-05-12 | $1.47M derived: sum of 2 quarters · filed 2016-03-15 | $2.49M derived: sum of 3 quarters · filed 2016-03-15 | $3.15M derived: sum of 4 quarters · filed 2016-03-15 | ||
| 2013-12-31 | $669.65K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $1.69M derived: sum of 2 quarters · filed 2016-03-15 | $2.35M derived: sum of 3 quarters · filed 2016-03-15 | $3.04M 10-K · filed 2016-03-15 | $3.04M 10-K · filed 2014-03-17 | |
| 2013-09-30 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $1.68M derived: sum of 2 quarters · filed 2013-11-12 | $2.38M 10-Q · filed 2013-11-12 | $2.78M derived: sum of 4 quarters · filed 2015-03-11 | ||
| 2013-06-30 | $659.85K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $1.35M 10-Q · filed 2013-08-09 | $1.75M derived: sum of 3 quarters · filed 2015-03-11 | $2.27M derived: sum of 4 quarters · filed 2015-03-11 | ||
| 2013-03-31 | $691.95K 10-Q · filed 2014-05-12 | $1.09M derived: sum of 2 quarters · filed 2015-03-11 | $1.61M derived: sum of 3 quarters · filed 2015-03-11 | $2.06M derived: sum of 4 quarters · filed 2015-03-11 | ||
| 2012-12-31 | $402.83K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-11 | $914.43K derived: sum of 2 quarters · filed 2015-03-11 | $1.37M derived: sum of 3 quarters · filed 2015-03-11 | $1.84M 10-K · filed 2015-03-11 | ||
| 2012-09-30 | $511.61K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $967.70K derived: sum of 2 quarters · filed 2013-11-12 | $1.44M 10-Q · filed 2013-11-12 | $1.99M derived: sum of 4 quarters · filed 2014-03-17 | ||
| 2012-06-30 | $456.09K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $929.53K 10-Q · filed 2013-08-09 | $929.26K 10-Q · filed 2012-08-09 | $1.48M derived: sum of 3 quarters · filed 2014-03-17 | $1.89M derived: sum of 4 quarters · filed 2014-03-17 | |
| 2012-03-31 | $473.43K 10-Q · filed 2013-05-10 | $1.02M derived: sum of 2 quarters · filed 2014-03-17 | $1.43M derived: sum of 3 quarters · filed 2014-03-17 | |||
| 2011-12-31 | $546.50K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | $956.14K derived: sum of 2 quarters · filed 2014-03-17 | $1.80M 10-K · filed 2014-03-17 | |||
| 2011-09-30 | $409.64K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $1.26M 10-Q · filed 2012-11-09 | ||||
| 2011-06-30 | $846.27K 10-Q · filed 2012-08-09 | |||||
| 2010-12-31 | $1.09M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |